2009 Annual Stockholders Meeting

2009 Proxy Statement (PDF)
2008 Annual Report (PDF)

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. Arena is not responsible for the content of this linked page.

Arena is a clinical-stage biopharmaceutical company committed to discovering and developing innovative therapies offering significant medical advances and new options for patients. We are focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Our lead drug candidate, lorcaserin hydrochloride, is intended for the treatment of obesity and is being evaluated in a Phase 3 clinical trial program. Our broad pipeline of novel compounds target G protein-coupled receptors (GPCRs), an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc. and Ortho-McNeil-Janssen Pharmaceuticals, Inc.